HOME - BioPhoenix Co.

NEWSROOM

三福生醫獲Up Therapeutics授權開發癌症新藥；CAR-T先驅成立Dispatch Bio獲2.16億美元投資；FDA批准首款慢性手濕疹非類固醇藥物Delgocitinib

2025/07/24

BioPhoenix Secures U.S. Up Therapeutics License to Develop Novel Proteasome Inhibitor Against Cancer

BioPhoenix, a subsidiary of San Fu Chemical’s San Fu Biotech, announced on the 24th that it has signed a licensing agreement with U.S.-based innovative drug developer Up Therapeutics. BioPhoenix has acquired global development, manufacturing, and commercialization rights for Up284, a first-in-class small molecule drug targeting solid tumors such as ovarian cancer. Both parties plan to submit an IND application and initiate Phase 1 clinical trials within the next 18 months.

Innovation Integrity Simplicity

Our Mission: Safeguarding Public Health through Innovation
We firmly believe that the value of innovation lies in its ability to create a better life. Therefore, we continuously invest in the research and development of cutting-edge technologies, combining profound market insights with user-centric design to create intelligent, convenient, and effective health products. Our goal is not only to meet current needs but also to actively shape a healthier future, ensuring that every innovation becomes a solid foundation for enhancing public health and well-being.

About BioPhoenix

BioPhoenix Co. (BPC), an innovative pharmaceutical company, was established in 2025 through the spin-off of San Fu Biotech, a subsidiary of San Fu Chemical Co. (TWSE: 4755), a publicly listed company in Taiwan. BPC is committed to high-value new drug development by leveraging a professional team and integrating innovative R&D resources. The company focuses on accelerating the launch of novel small molecule drugs (NCEs) that address unmet medical needs in three major global therapeutic areas: ophthalmology, immunology, and oncology. Our mission is to deliver impactful treatment solutions and become a force for societal good through innovation in drug discovery and development.

INNOVATION & RESEARCH Development

By leveraging our professional team and the Leverage Research Co-Development (LRCD) model, we accelerate the development and launch of novel therapies. This approach enables us to deliver solutions for unmet medical needs across the world's three major therapeutic areas, improving the lives of patients and their families globally.

Autoimmune Disease

10% of the population suffers from autoimmune diseases

Oncology

Every minute, 37 cancers are newly diagnosed with cancer

Ophthalmology

2.2 billion people suffer from eye diseases